^
BIOMARKER:

POLE mutation

i
Other names: POLE1, DNA Polymerase Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit A, Polymerase (DNA) Epsilon Catalytic Subunit, DNA Polymerase II Subunit A, Polymerase (DNA Directed) Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit Protein, Polymerase (DNA Directed) Epsilon
Entrez ID:
Related biomarkers:
POLE mutation
Endometrial Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
POLE mutation
Gastric Cancer
CP-675206
Sensitive: C2 – Inclusion Criteria
POLE mutation
Gastric Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
POLE mutation
Solid Tumor
avelumab
Sensitive: C2 – Inclusion Criteria
POLE mutation
Endometrial Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
POLE mutation
Solid Tumor
toripalimab
Sensitive: C2 – Inclusion Criteria
POLE mutation
CRC
nivolumab
Sensitive: C2 – Inclusion Criteria
POLE mutation
Solid Tumor
dostarlimab
Sensitive: C2 – Inclusion Criteria
POLE mutation
Melanoma
PD1 inhibitor + PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
Cholangiocarcinoma
PD1 inhibitor + PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
NSCLC
PD1 inhibitor + PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
CRC
PD1 inhibitor + PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
Melanoma
PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
Cholangiocarcinoma
PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
CRC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
Cholangiocarcinoma
PD1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
CRC
PD1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
CRC
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
POLE mutation
Endometrial Cancer
nivolumab
Sensitive: C4 – Case Studies